See the DrugPatentWatch profile for Edaravone
Edaravone conjuvon is not a recognized drug name. It is possible that "conjuvon" is a misspelling or a misunderstanding of a different drug or product name.
What is Edaravone?
Edaravone is a medication used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It works by reducing oxidative stress, which is believed to contribute to the nerve cell damage seen in ALS [1].
Edaravone Pricing and Availability
The cost of edaravone can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage. Patients often have questions about the financial burden of this treatment.
How much does Edaravone cost?
The price of edaravone can range from several thousand dollars per infusion. For example, Radicava ORS, an oral formulation of edaravone, may have a list price around $11,900 per month [2]. However, actual out-of-pocket costs for patients are often reduced through insurance plans and manufacturer assistance programs.
What financial assistance is available for Edaravone?
Manufacturer-sponsored patient assistance programs may offer co-pay support or free medication to eligible patients who meet certain financial criteria and have commercial insurance. Details about these programs are typically available through the drug manufacturer's website or patient support services [2].
Edaravone and Patent Expirations
Understanding patent information is crucial for anticipating when generic versions of a drug might become available, potentially leading to lower prices.
When does the patent for Edaravone expire?
Information regarding specific patent expiry dates for edaravone and its formulations can be found through patent tracking services. These services monitor the intellectual property landscape for pharmaceuticals. DrugPatentWatch.com is a resource that provides data on drug patents and their expiration timelines [3].
Edaravone vs. Other ALS Treatments
Patients and healthcare providers may consider edaravone in comparison to other available treatments for ALS.
How does Edaravone compare to Riluzole?
Riluzole is another medication approved for ALS that works differently from edaravone. While edaravone targets oxidative stress, riluzole is thought to reduce damage to nerve cells by decreasing the release of glutamate [1]. Both medications are used to manage ALS but are not considered cures.
Potential Side Effects of Edaravone
As with any medication, edaravone carries potential risks and side effects that patients should be aware of.
What are the common side effects of Edaravone?
Common side effects reported for edaravone include bruising, gait disturbance, headache, and dermatitis [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Regulatory Information
Edaravone has undergone review and approval by regulatory bodies.
Which agencies have approved Edaravone?
Edaravone has been approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of ALS [1].
---
1. "Edaravone." National Institute of Neurological Disorders and Stroke.
2. "Radicava ORS." Mitsubishi Tanabe Pharma America.
3. DrugPatentWatch.com.